Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980648 | 1.00 | PPARA (0.54) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL24073320 | 0.91 | SYK (0.54) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL7965696 | 0.90 | PPARA (0.56) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL7297130 | 0.90 | PPARA (0.56) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL3004720 | 0.88 | PPARA (0.58) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL1093029 | 0.88 | PPARA (0.58) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL5033775 | 0.88 | PPARA (0.58) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL14211452 | 0.86 | PPARA (0.57) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL4370045 | 0.86 | KLK5 (0.65) | PPARAKLK5KLK7CTSSSYK | |
| SCHEMBL20144655 | 0.85 | CACNA1B (0.59) | PPARAKLK5KLK7CTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513054-B1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8552032-B2 | Bicyclic derivatives useful as inhibitors of DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-08 | — | — | US | disclosed |
| EP-2513054-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152321-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA (BE) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075634-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152321-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | DPP4, DPP7, DPP3 | PPARA 368/4885KLK5 3521/4885KLK7 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.